COVID-19 Treatment-Current Status, Advances, and Gap

Area of Science:

• Virology
• Infectious Diseases
• Drug Discovery

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, has led to significant global mortality and socioeconomic disruption.
• Existing therapeutic options for COVID-19 are limited, with only a few FDA-approved drugs like Remdesivir and Baricitinib available.
• There is an urgent need to expand therapeutic strategies to combat the ongoing pandemic.

Purpose of the Study:

• To review current research efforts in developing novel treatments for COVID-19.
• To discuss promising therapeutic approaches targeting viral entry and life cycle disruption.
• To identify gaps in current COVID-19 treatment research and suggest future directions.

Main Methods:

• Literature review of recent studies on COVID-19 therapeutics.
• Analysis of strategies aimed at inhibiting SARS-CoV-2 entry into host cells.
• Examination of approaches targeting the SARS-CoV-2 replication cycle.

Main Results:

• Several promising therapeutic strategies are under investigation, including those that block viral attachment and fusion.
• Disrupting the SARS-CoV-2 life cycle through interventions in viral RNA replication and protein processing shows potential.
• The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative is advancing clinical trials for new drugs.

Conclusions:

• Broadening therapeutic approaches beyond existing options is crucial for effective COVID-19 management.
• Targeting viral entry and life cycle presents viable avenues for novel antiviral development.
• Further research is needed to fill existing gaps and develop a comprehensive arsenal against SARS-CoV-2.